Incyte's Tafasitamab Shows Positive Results in Lymphoma Study

Aug 15, 2024, 08:36 PM

Incyte has announced positive topline results from a pivotal study of its blood cancer drug, Tafasitamab (Monjuvi®), in patients with relapsed or refractory follicular lymphoma. This development marks a significant advancement in the treatment of this type of lymphoma, which is often difficult to manage. The study's success adds to Incyte's growing portfolio of post-transplant drugs, enhancing its position in the oncology market.